Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Costanza, Mariantonia Dr. (1) Daniel, Peter Prof. Dr. (1) Dörr, Jan Rafael (1) Hinze, Christian Dr. med. Dipl.-Math. (1) Kühn, Ralf Dr. (1) Lusatis, Simone (1) Scheidereit, Claus Prof. Dr. (1) Schmitt, Clemens Prof. Dr. (14) Schreiber, Adrian PD Dr. med. (1) Sczakiel, Henrike (1) Specker, Edgar Dr. (1) von Kries, Jens Peter Dr. (1) Wollert-Wulf, Brigitte (2) (-) Janz, Martin Dr. (8) (-) Mathas, Stephan Dr. (8) Bioinformatics and Omics Data Science (1) (-) Biologie maligner Lymphome (11) Experimentelle Ultrahochfeld-MR (6) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Genomics (1) Kardiale MRT (6) Magnetic Resonance (6) Molekularbiologie von Hormonen im Herz-Kreislaufssystem (2) Molekulare Herz- Kreislaufforschung (1) Proteomics (1) (-) Tumorgenetik und zelluläre Stressantworten (1) 1999 (2) 2000 (2) 2001 (1) 2002 (6) 2003 (3) 2004 (3) 2005 (3) (-) 2006 (5) 2007 (4) 2008 (4) 2009 (4) 2010 (3) 2011 (4) 2012 (2) 2013 (3) 2014 (2) 2015 (5) 2016 (3) (-) 2017 (5) (-) 2018 (1) 2019 (3) 2020 (6) 2021 (3) 2022 (7) 2023 (10) 2024 (2) 11 Ergebnisse: Active Filter: Janz, Martin Dr.Mathas, Stephan Dr.Biologie maligner LymphomeTumorgenetik und zelluläre Stressantworten200620172018 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. September 2018 / Leukemia The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma N. Schleussner O. Merkel M. Costanza H.C. Liang F. Hummel C. Romagnani P. Durek I. Anagnostopoulos M. Hummel K. Jöhrens A. Niedobitek P.R. Griffin R. Piva H.L. Sczakiel W. Woessmann C. Damm-Welk C. Hinze D. Stoiber B. Gillissen S.D. Turner E. Kaergel L. von Hoff M. Grau G. Lenz B. Dörken C. Scheidereit L. Kenner M. Janz S. Mathas 05. Januar 2017 / Blood Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma J. Du M. Neuenschwander Y. Yu J.H.M. Däbritz N.R. Neuendorff K. Schleich A. Bittner M. Milanovic G. Beuster S. Radetzki E. Specker M. Reimann F. Rosenbauer S. Mathas P. Lohneis M. Hummel B. Dörken J.P. von Kries S. Lee C.A. Schmitt 01. Dezember 2017 / Lancet Oncol Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group D.A. Eichenauer A. Plütschow S. Kreissl M. Sökler J.C. Hellmuth J. Meissner S. Mathas M.S. Topp K. Behringer W. Klapper G. Kuhnert M. Dietlein C. Kobe M. Fuchs V. Diehl A. Engert P. Borchmann 13. Dezember 2017 / J Neurosci Graded elevation of c-Jun in Schwann cells in vivo: gene dosage determines effects on development, remyelination, tumorigenesis, and hypomyelination S.V. Fazal J.A. Gomez-Sanchez L.J. Wagstaff N. Musner G. Otto M. Janz R. Mirsky K.R. Jessen 01. April 2017 / Br J Haematol Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012) N. Baras S. Dahm J. Haberland M. Janz K. Emrich K. Kraywinkel A. Salama Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. September 2018 / Leukemia The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma N. Schleussner O. Merkel M. Costanza H.C. Liang F. Hummel C. Romagnani P. Durek I. Anagnostopoulos M. Hummel K. Jöhrens A. Niedobitek P.R. Griffin R. Piva H.L. Sczakiel W. Woessmann C. Damm-Welk C. Hinze D. Stoiber B. Gillissen S.D. Turner E. Kaergel L. von Hoff M. Grau G. Lenz B. Dörken C. Scheidereit L. Kenner M. Janz S. Mathas
05. Januar 2017 / Blood Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma J. Du M. Neuenschwander Y. Yu J.H.M. Däbritz N.R. Neuendorff K. Schleich A. Bittner M. Milanovic G. Beuster S. Radetzki E. Specker M. Reimann F. Rosenbauer S. Mathas P. Lohneis M. Hummel B. Dörken J.P. von Kries S. Lee C.A. Schmitt
01. Dezember 2017 / Lancet Oncol Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group D.A. Eichenauer A. Plütschow S. Kreissl M. Sökler J.C. Hellmuth J. Meissner S. Mathas M.S. Topp K. Behringer W. Klapper G. Kuhnert M. Dietlein C. Kobe M. Fuchs V. Diehl A. Engert P. Borchmann
13. Dezember 2017 / J Neurosci Graded elevation of c-Jun in Schwann cells in vivo: gene dosage determines effects on development, remyelination, tumorigenesis, and hypomyelination S.V. Fazal J.A. Gomez-Sanchez L.J. Wagstaff N. Musner G. Otto M. Janz R. Mirsky K.R. Jessen
01. April 2017 / Br J Haematol Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012) N. Baras S. Dahm J. Haberland M. Janz K. Emrich K. Kraywinkel A. Salama